Core Viewpoint - Heng Rui Pharmaceutical officially listed on the Hong Kong Stock Exchange on May 23, 2023, marking a significant milestone in its internationalization strategy and achieving the largest financing scale in the Hong Kong pharmaceutical sector since 2020 [1][9]. Group 1: Listing Details - Heng Rui Pharmaceutical's IPO involved a global offering of approximately 225 million H-shares at an issue price of HKD 44.05, raising approximately HKD 9.89 billion [1]. - The stock opened at HKD 57 per share, a 29.4% increase from the issue price, and closed at HKD 55.15, a 25.2% increase [1]. - The listing is the second largest IPO in Hong Kong for 2025, following the leading battery manufacturer CATL [1]. Group 2: Company Leadership and Strategy - Vice Chairman Dai Hongbin emphasized that the listing is a crucial step for Heng Rui to enter the international capital market and accelerate its innovation and internationalization [2][3]. - The company aims to leverage this listing to enhance its global cooperation network and continue its focus on innovative research and development [3][10]. - Dai Hongbin's recent appointment as Vice Chairman reflects a strategic shift in the company's leadership, allowing him to play a more significant role in external communications and strategic planning [6]. Group 3: Historical Context and Future Outlook - Heng Rui Pharmaceutical, founded in 1970, has evolved from a local pharmaceutical factory to a significant player in the Chinese pharmaceutical industry, previously reaching a market value of over 600 billion yuan [7]. - The company has established 14 R&D centers globally and initiated over 20 overseas clinical trials, indicating its commitment to international expansion [10]. - The funds raised from the IPO will support clinical research and the development of innovative platforms, aiming to create first-in-class and best-in-class products [11].

每经记者｜吴永久 每经编辑｜闫峰峰 周五，A股三大指数集体回调，在午后上证指数出现一波急跌，截至收盘，沪指跌0.94%，收报3348.37点。上涨股票1107只，下跌股票4204只，其中可控 核聚变概念表现出色。 在每日经济新闻App举办的掘金大赛中，第60期比赛于周五结束，本期比赛时间共5天。其中冠军收益率28.38%，亚军收益率27.28%，季军收益率 26.60%。本期比赛共460名选手取得正收益，他们都将获得现金奖励。 如果您的税前获奖金额超出100元，则需要报税，需获奖用户提供真实姓名、身份证号和手机号等信息以便报税。本期比赛奖励将于5月26日发放，恭喜大 家获奖。奖励查询方式：在每日经济新闻App的主页上，点击右上角的"个人中心"（右上角头像），在"我的钱包"就可查询奖励，支付宝提现。 好消息来了，第61期比赛从周六开始报名，大赛为模拟炒股，模拟资金50万元。报名时间为5月24日到5月30日，比赛时间为5月26日到5月30日。正收益就 获奖，报名就拿福利！周周发奖金，月月有大奖！ 高手抓住可控核聚变、宠物经济行情，看好高股息资产 从亚军的操作来看，他抓住了宠物经济天元宠物的行情，在周一，他以33. ...

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index closing up 0.24% at 23,601.26 points, while the Hang Seng Tech Index fell 0.09% to 5,246.87 points. The total trading volume for the day was HKD 203.67 billion [1] - For the week, the Hang Seng Index rose 1.1%, while the Hang Seng China Enterprises Index increased by 1.36%, and the Hang Seng Tech Index declined by 0.65% [1] Blue-Chip Stocks Performance - BYD Company (01211) reached a new high, closing up 1.97% at HKD 465.2, contributing 18.25 points to the Hang Seng Index. The company reported a 169% year-on-year increase in electric vehicle registrations for April [2] - Other notable blue-chip stocks included CSPC Pharmaceutical Group (01093) up 2.16%, WH Group (00288) up 2.16%, while Chow Tai Fook (01929) fell 3.32% [2] Sector Highlights - The pharmaceutical sector saw significant gains, with Hengrui Medicine (noted for its IPO) surging over 25% on its debut, reflecting strong market confidence [3][4] - Gold stocks turned positive in the afternoon, with Lingbao Gold (03330) rising 9.16% and other gold-related stocks also showing gains [4][5] - The automotive sector experienced an upward trend, with BYD and Great Wall Motors (02333) both reporting increases in stock prices [5][6] New Listings - Hengrui Medicine (01276) debuted strongly, closing up 25.2% at HKD 55.15, with a total issuance of 225 million shares and net proceeds of approximately HKD 9.75 billion [10] - MIRXES-B (02629) also performed well, closing up 28.76% at HKD 30, with net proceeds of about HKD 880 million from its share issuance [11]

创新药沪深港ETF（517110）今日盘中涨超2%。 东海证券表示，海外方面，特朗普签署行政命令要求制药企业按照"最惠国待遇"定价，若实施可能打破 现行国际药价梯度，长期或推动全球药企调整定价策略。我国创新药具备研发成本低、效率高的优势， 有望成为BD交易首选，加速向"创新主导"转型；CXO产业链或进一步巩固市场地位。仿制药领域，美 国市场若因价格压缩出现供应短缺，我国具备ANDA批件的仿制药企业或迎来份额提升机遇。 后续来看，受益于创新药出海交易、人工智能赋能医药全产业链、创新药丙类医保目录落地等，创新药 板块盈利和估值有望迎来双升。覆盖三地优质上市创新药企的创新药沪深港ETF（517110）值得关注。 同时，在国内集采政策优化、医疗设备招标复苏、内需复苏等积极因素推动下，医药板块的情绪和估值 抬升的空间或进一步打开。 创新药沪深港ETF（517110）跟踪的是SHS创新药(人民币)指数（931409），该指数由中证指数有限公 司编制，从A股市场中选取主营业务涉及创新药物研发、生产及销售的上市公司证券作为指数样本，覆 盖医药生物行业。该指数旨在反映A股市场中创新药相关企业的整体表现，其成分股具有显著的研发投 ...

消息面上，在创新治疗领域，中国企业的国际合作一直在持续。此前，百利天恒将双抗AD授权给百时 美施贵宝，以84亿美元的金额刷新了中国ADC新药"出海"的交易金额纪录。而刚实现"A+H"两地上市的 恒瑞医药近年来的BD更是进展迅速。截至目前，恒瑞医药已经实现14笔创新药License-out（对外授 权），其中近三年对外授权9笔，合作方包括默克、默沙东等国际巨头，涉及GLP-1、ADC等热门领 域。2024年中国创新药对License-out完成94笔，出海交易总金额高达519亿美元，同比增长26%。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 中信建投证券认为，创新药板块近年来展现出强劲的技术驱动发展势头，尤其在抗体偶联药物 （ADC）、双特异性抗体（双抗）以及小分子疗法等领域取得了显著进展。以2025年美国临床肿瘤学 会（ASCO）年会为例，中国创新药企在此次会议上提交了超过70项口头报告，其中Late Breaking Abstra ...

超级赛道大爆发。 今日，港股医药板块全线爆发，昭衍新药最高大涨超16%，泰格医药大涨超12%，绿叶制药一度大涨超11%。 A股创新药板块亦集体走强，海辰药业斩获20cm涨停，众生药业涨停。 消息面上，多家创新药企业宣布将在5月30日至6月3日举办的2025年美国临床肿瘤学会(ASCO)年会上展示创新 药物研究成果。另有分析称，受益于三生制药与辉瑞达成的PD-1/VEGF双抗SSGJ-707全球权益合作的消息催 化，中国创新药企通过技术授权加速融入全球产业链，市场对于国产创新药出海预期被放大。 展望后市，有券商机构认为，目前我国创新药进入成果兑现阶段，研发进展催化较多，有望持续作为2025年医 药板块投资主线。2025年将成为医药行业"三个元年"——收入放量元年（医保谈判后产品加速放量）、盈利跨 越元年（成批企业进入盈利期）、估值抬升元年（支付端改善拉长估值周期）。 全线大爆发 今日，港股开盘后，医药板块全线爆发，恒生医疗保健指数一度大涨超2%。成分股方面，海吉亚医疗一度大 涨超15%，绿叶制药最高涨超11%，康哲药业涨超9%，信达生物涨超7%，亚盛医药-B、金斯瑞生物科技涨超 5%。 与此同时，CRO概念股亦 ...

Group 1 - The core viewpoint of the news is that Heng Rui Pharmaceutical successfully completed its IPO in Hong Kong, with a final issue price of HKD 44.05 per share, representing a discount of nearly 27% compared to its A-share closing price on May 22 [1][2] - The IPO raised a total of HKD 98.9 billion, with a net amount of HKD 97.47 billion after deducting listing expenses, which will be used for R&D and expanding production facilities [2] - Heng Rui Pharmaceutical's stock price surged approximately 30% on its debut in Hong Kong, while its A-share price experienced a slight decline [1][2] Group 2 - Heng Rui Pharmaceutical is competing with BeiGene for the title of "innovative drug leader" in the A-share market, but it has not yet received approval for any innovative drugs overseas [3] - The company has engaged in nine licensing agreements over the past three years, generating approximately USD 14 billion in total transaction value, which has become a significant source of revenue [3] - The company's strategy includes enhancing its international presence through the Hong Kong listing, aiming for breakthroughs in overseas markets [4]

Group 1 - A-shares' three major indices turned positive, with the pharmaceutical sector showing overall positive sentiment on May 23 [1] - A500 ETF (512050) rose by 0.21% with a trading volume exceeding 1.1 billion yuan and a turnover rate over 7% [1] - Leading pharmaceutical stocks such as Tigermed, Kelun Pharmaceutical, Betta Pharmaceuticals, and CR Medical collectively strengthened, with Tigermed rising over 6% [1] Group 2 - China's innovative pharmaceutical companies are increasingly demonstrating global competitive advantages, particularly in overseas License-out transactions [2] - The emergence of the NewCo model has helped original pharmaceutical companies address challenges related to financing, monetization, and R&D risks [2] - Recent policy adjustments, including optimization of centralized procurement rules and increased support for innovative drugs, signal a favorable regulatory environment for the industry [2]

消息面上，2025年5月23日，中国医药行业的领军企业恒瑞医药正式在港交所挂牌上市。此次全球发 售，恒瑞医药将获得募集资金净额约98.9亿港元。对于这笔巨额资金的用途，恒瑞医药有着明确的规 划：约75%将用于研发计划，约15%用于在中国和海外市场建设新的生产和研发设施，以及扩大或升级 现有生产和研发设施，约10%用作营运资金及其他一般企业用途。这不仅标志着恒瑞医药发展历程中的 又一重大跨越，上市首日超27%的涨幅也体现了资金对港股创新药板块的关注和认可。 港股创新药板块高盈利持续消化估值。港股创新药指数2月21日市盈率为64倍，5月23日最新市盈率仅为 27倍，不足两个月前的一半，当前布局性价比突出。 中航证券认为，国产创新药板块展现出显著的投资价值。在创新药企业出海持续推进的背景下，国内创 新药行业正经历深刻变化，企业核心优势不断叠加，持续强化自身竞争力，逐步从创新追随者转变为国 际竞争中的重要力量，并从国内市场走向国际舞台。近年来，国内创新药研发呈现快速发展态势，截至 2024年12月31日，中国企业研发的活跃状态创新药数量累计已达3575个，超越美国成为全球首位。从临 床试验的数目来看，2015-202 ...

Group 1 - The core viewpoint of the news highlights the approval of a new innovative drug by Heng Rui Medicine, which is the first self-developed DPP-4 inhibitor combined with metformin in China, aimed at improving blood sugar control for adult patients with type 2 diabetes [1] - Following the announcement, Heng Rui Medicine's stock surged nearly 30% in the Hong Kong market, indicating strong investor confidence in the innovative drug sector [1] - The Hong Kong innovative drug index has seen a significant decrease in its price-to-earnings ratio from 64 times on February 21 to 25 times on May 22, suggesting a favorable investment opportunity in the sector [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the National Index for Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs [2] - The larger innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from advancements in AI, the internationalization of domestic innovative drugs, and the introduction of new healthcare policies [2] - According to Xingye Securities, the innovative drug sector in China is transitioning from a "follower" to a "leader," with significant advancements expected in new targets and technologies by 2025, showcasing strong global competitiveness in areas like ADC, bispecific antibodies, and cell therapy [2]